A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,901–3,000 of 3,967
Gao, Z., Cao, S., Yuan, H., Wu, J. Z., & Zou, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114337 · Cited by 2
Cardillo, C., Criner, G. J., & Gayen, S. K. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251326743 · Cited by 4
Genecand, L., Wacker, J., Guerreiro, I., Lechartier, B., Beghetti, M., Pohle, S., Darie, A. M., Lichtblau, M., Ulrich, S., Guler, S. A., et al. (2025) · Respiration · doi:10.1159/000544800 · Cited by 2
A Twist in the Fibrotic Tale: The Overlooked Vasculopathy in Idiopathic Pulmonary Fibrosis
Tonelli, A. R., & Sahay, S. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202502-0465ed · Cited by 2
Advances in management of pulmonary fibrosis
Lachowicz, J. A., Steinfort, D., Smallwood, N., & Prasad, J. D. (2025) · Internal Medicine Journal · doi:10.1111/imj.70051 · Cited by 3
Wang, Y., Fan, W., Guo, Y., Sun, L., Hu, Y., Chen, J., Gong, L., & Xie, Z. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117768 · Cited by 2
Chang, S., Wen, S., Zhang, W., Zhang, H.-F., Guo, Y. M., Wang, Q., Hu, X., Liu, Z., Sun, Y., & Yang, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1573241 · Cited by 4
“Phase III clinical trials have shown PFD’s efficacy in IPF, including a slowdown in lung function decline and reduced mortality risk (12, 13).”
Kondoh, Y., Ito, T., Kimura, H., Bao, H., & Kuwana, M. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03713-x · Cited by 6
Kaneko, T., Okuda, R., Takemura, T., Iwasawa, T., Haga, S., Takeda, Y., Hagiwara, E., & Ogura, T. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.004 · Cited by 3
Morrison, H. G., Dao, K., Holte, D., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00065 · Cited by 2
Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis
Niitsu, T., Fukushima, K., Komukai, S., Yamamoto, R., Shiroyama, T., Nii, T., Takata, S., Hashimoto, K., Abe, Y., Hirata, H., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108347 · Cited by 3
When Malignancies Mimic Interstitial Lung Disease: A Case Series and Review of the Literature
Guler, S. A., & Berezowska, S. (2015) · Journal of Clinical Respiratory Diseases and Care · doi:10.4172/2472-1247.1000104 · Cited by 2
Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice
Ma, H., Qiao, S., Wang, Z., Geng, S., Zhao, Y., Hou, X., Tian, W., Chen, D., & Yao, L. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2016 · Cited by 2
Palliative and end of life care in idiopathic pulmonary fibrosis
Newell, K. A., Smith, K., & Russell, A. (2018) · Primary Health Care · doi:10.7748/phc.2018.e1387 · Cited by 2
The cardiovascular system in idiopathic pulmonary fibrosis
Chong, S. G., Yanagihara, T., & Kolb, M. R. J. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028319 · Cited by 2
Azuma, A., & Richeldi, L. (2020) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2020.0005 · Cited by 2
Al-Ansari, S., Borowski, A. G., Fuad, A., Alawadhi, O., Riaz, H., Sharma, V., Khan, N. A., Southern, B. D., & Tang, W. H. W. (2020) · Journal of Interdisciplinary Medicine · doi:10.2478/jim-2020-0009 · Cited by 2
Phase three clinical trials in idiopathic pulmonary fibrosis
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882299 · Cited by 2
Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?
Corrie, L., Muzaffar-Ur-Rehman, M., Kukatil, L., Devasari, M., & Shirisha, A. (2021) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x17666210304100043 · Cited by 2
Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems
Farrand, E. D., & LIMPER, A. H. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.006 · Cited by 2
Anderson, M. R., Aronson, K. I., Diamond, J. M., Christie, J. D., & Singer, J. P. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202201-019rl · Cited by 2
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply.
Richeldi, L., Stowasser, S., & Maher, T. M. (2022) · PubMed · doi:10.1056/nejmc2209529 · Cited by 1
Holland, A. E., & Swigris, J. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_16 · Cited by 2
Self-citationPirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis
Miura, Y., & Azuma, A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1029453 · Cited by 2
Challenges in IPF diagnosis, current management and future perspectives: Patient case 2.
Margaritopoulos, G. A. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 2
Elements: in this month’s issue
Donnelly, S. C. (2015) · QJM · doi:10.1093/qjmed/hcv147 · Cited by 2
Schuetze, K. B., & McKinsey, T. A. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00167.2015 · Cited by 2
Shintani, Y., Endo, D., Kumasawa, F., et al. (2015) · Journal of Nihon University Medical Association · doi:10.4264/numa.74.69 · Cited by 2
European IPF Patient Charter: an SOS to the world
Crestani, B. (2016) · European Respiratory Journal · doi:10.1183/13993003.01902-2015 · Cited by 2
Kolb, M. R. J., Jenkins, G. R., & Richeldi, L. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-208670 · Cited by 2
Pruebas de función pulmonar en la fibrosis pulmonar idiopática: ¿más allá de la espirometría?
Casán, P., González, C. M., & Ancochea, J. (2016) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.02.017 · Cited by 3
Audibert, C., Livoti, C., & Cazé, A. (2016) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2016.04.008 · Cited by 2
Handa, T., & Azuma, A. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_9 · Cited by 2
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
Cerri, S., Sgalla, G., Richeldi, L., et al. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-0916-5 · Cited by 2
“Nowadays, the mainstream IPF treatment is based on drugs with antifibrotic activity, such as pirfenidone and nintedanib, which have shown meaningful slowing of the rate of disease progression as measured by the rate of FVC decline [8, 9].”
BackgroundBerngard, S. C., & Afshar, K. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.31 · Cited by 1
CPFE: distinctive and non-distinctive features
Wells, A. U., Margaritopoulos, G. A., Antoniou, K. M., Nunès, H., & Costabel, U. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005915 · Cited by 2
Palliative and End-of-Life Care in Idiopathic Pulmonary Fibrosis
Lindell, K. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00008-2 · Cited by 3
Rees, C. J., Pollack, C. V., & Riese, V. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-63895-9_40 · Cited by 2
Interstitial Lung Disease in the Elderly: A Review of Pathogenesis and Clinical Management
Patterson, K. C. (2018) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000270 · Cited by 2
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
Pasciuto, G., Inchingolo, R., Condoluci, C., Magnini, D., Iovene, B., & Richeldi, L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0209-0 · Cited by 2
Carrera, L. G., & Walther, R. Á.-S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.06.002 · Cited by 2
ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine
Michaud, G. C., Channick, C. L., Marion, C. R., Tighe, R. M., Town, J. A., Luks, A. M., Richards, J. B., Kher, S., Mota, P., Hong, G., et al. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201504-194cme · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“Meanwhile, two anti-fibrotic drugs, pirfenidone and nintedanib, showed to slow down the functional decline in IPF and they were approved by the US FDA in 2014 [13,14].”
BackgroundMethodInterstitial Lung Disease and ANCA-Associated Vasculitis
Flores-Suárez, L. F., & Sacoto, G. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00127-9 · Cited by 2
Dhar, R. (2019) · Lung India · doi:10.4103/lungindia.lungindia_379_19 · Cited by 2
Shen, L., Yan, Q., & Chen, X. (2019) · Archives of Rheumatology · doi:10.46497/archrheumatol.2020.7381 · Cited by 7
Molecular approach to the classification of chronic fibrosing lung disease—there and back again
Verleden, S. E., Braubach, P., Kühnel, M., Dickgreber, N. J., Brouwer, E., Tittmann, P., Laenger, F., & Jonigk, D. D. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02964-9 · Cited by 2
“Nintedanib, approved in 2014, also slows down the FVC decline [10].”
BackgroundInfluentialKatano, T., Sekine, A., Ikeda, S., Yamakawa, H., Misumi, T., Okabayashi, H., Okuda, R., Kitamura, H., Baba, T., Komatsu, S., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.01.002 · Cited by 3
Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Soskis, A., & Hallowell, R. W. (2021) · Respiration · doi:10.1159/000515607 · Cited by 2
Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?
Vašáková, M. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.151 · Cited by 2
Sakamoto, N., Hamada, N., Okamoto, M., Tobino, K., Ichiyasu, H., Ishii, H., Ichikado, K., Morimoto, S., Hosogaya, N., & Mukae, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047249 · Cited by 3
Wilson, A. M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Hammond, M., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08090 · Cited by 3
Pulmonary Fibrosis Progression Prediction Using Image Processing and Machine Learning
Abo-eleneen, A., Patel, M. K., & Al-Maadeed, S. A. (2021) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-030-14647-4_11 · Cited by 2
Palliative Care in Interstitial Lung Disease
Wijsenbeek, M. S., & Moor, C. C. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_11 · Cited by 2
Palliative Care in Lung Disease
FERRELL, B. R., & Harrington, A. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_1 · Cited by 2
Review of the British Thoracic Society Winter Meeting 2014, 3-5 December, London, UK
Greening, N. J., José, R. J. P., Chalmers, J. D., & Janes, S. M. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-206784 · Cited by 1
The Safety and Tolerability of Pirfenidone in Indian Patients with Idiopathic Pulmonary Fibrosis
Nair, A. A., Gupta, R., James, P., Irodi, A., Christopher, D. J., & Thangagunam, B. (2022) · Current Medical Issues · doi:10.4103/cmi.cmi_89_21 · Cited by 2
Rezaee, R., & Hosseinzadeh, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00131-6 · Cited by 2
Cottin, V., & Valenzuela, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006115 · Cited by 3
Developments in the management of idiopathic pulmonary fibrosis
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.7.0337 · Cited by 2
Majewski, S., Królikowska, M., Costabel, U., Piotrowski, W. J., & Ochman, M. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/4054339 · Cited by 2
Górska, K., Maskey‐Warzęchowska, M., Barnaś, M., Białas, A. J., Barczyk, A., Jagielska-Len, H., Jassem, E., Kania, A., Lewandowska, K. B., Majewski, S., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221117982 · Cited by 2
Matson, S. M., Lee, J. S., & Fontenot, A. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00072-1 · Cited by 2
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00514-z · Cited by 3
Capaccione, K. M., & Salvatore, M. M. (2023) · Clinical Imaging · doi:10.1016/j.clinimag.2023.07.002 · Cited by 2
Inhaled nintentanib, Pirfenidone and Macitentan for Pulmonary Fibrosis: a Laboratory Experiment
Zarogoulidis, P., Petridis, D., Huang, H., Bai, C., Oikonomou, P., Nikolaou, C., Matthaios, D., Perdikouri, Ε.-I., Papadopoulos, V., Petanidis, S., et al. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0045 · Cited by 2
Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis
Johnston, J., & Rivera‐Ortega, P. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202305-483ed · Cited by 2
Current and Future Therapies for Idiopathic Pulmonary Fibrosis
Spagnolo, P., Bonella, F., Vašáková, M., Kreuter, M., & Maher, T. M. (2015) · Pulmonary Therapy · doi:10.1007/s41030-015-0009-4 · Cited by 2
Khor, Y. H., Ng, Y., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012647 · Cited by 2
Emerging and potential treatment options for sarcoidosis
Bandyopadhyay, D., & Judson, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1411260 · Cited by 2
New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis
Kwon, B. S., & Song, J. W. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.2.173 · Cited by 2
Interstitial lung disease: perhaps unclassifiable, but not untreatable
Oldham, J. M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30343-1 · Cited by 2
Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?
Ghose, M., & Islam, T. (2020) · Bangladesh Critical Care Journal · doi:10.3329/bccj.v8i2.50028 · Cited by 2
Macisaac, S., & Kolb, M. R. J. (2021) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2021.1899775 · Cited by 2
The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience
Benfante, A., Messina, R., Piccionello, I., Liberti, R., Principe, S., & Scichilone, N. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102038 · Cited by 2
Johannson, K. A., Collard, H. R., & Richeldi, L. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.014 · Cited by 2
Tomassetti, S., Sebastiani, A., Caminati, A., Oggionni, T., Davì, M., Ghirardini, A., & Martinoli, M. M. (2021) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v38i3.11400 · Cited by 3
Kostorz‐Nosal, S., Jastrzębski, D., Kubicki, P., Galle, D., Gałeczka‐Turkiewicz, A., Toczyłowska, B., & Ziora, D. I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133657 · Cited by 2
McLoud, T. C. (2015) · Radiographics · doi:10.1148/rg.2015150034 · Cited by 3
Idiopathic pulmonary fibrosis: The current state of the problem
Shmelev, E. I. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh20168812103-108 · Cited by 2
Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?
Maher, T. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01403-2017 · Cited by 2
Qi, X.-M., Wang, F., & Chen, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101521 · Cited by 2
Pulmonary and Critical Care Medicine
Kruse, D. A., & Bailey, K. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_25 · Cited by 2
Stylianou, P., Rushwan, S., Wang, W., Miah, M. A., Darweesh, O., MacKinnon, A. C., Roach, K. M., Hitchman, C. J., Gonchar, O., Thorpe, S. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503154 · Cited by 2
GATA1-defective immune-megakaryocytes as possible drivers of idiopathic pulmonary fibrosisPreprint
Gobbo, F., Zingariello, M., Verachi, P., Falchi, M., Arciprete, F., Martelli, F., Peli, A., Mazzarini, M., Viestra, J., Mead‐Harvey, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.20.542249 · Cited by 4
MacKenzie, B., Mahavadi, P., de Sá, Y. A. P. J., Creyns, B., Coelho, A. L., Espíndola, M. S., Ruppert, C., Hötzenecker, K., Hogaboam, C. M., & Günther, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.24.589970 · Cited by 2
A Nerve-Fibroblast Axis in Mammalian Lung FibrosisPreprint
Ishikawa, G., Peng, X., Ghincea, A., McGovern, J., Zielonka, J., Jeevanandam, A., Shao, S., Woo, S., Okuno, D., Yu, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.09.611003 · Cited by 3
Rare Variants and Survival of Patients with Idiopathic Pulmonary FibrosisPreprint
Alonso-González, A., Jáspez, D., Lorenzo-Salazar, J. M., Ma, S., Strickland, E., Mychaleckyj, J. C., Kim, J. S., Huang, Y., Adegunsoye, A., Oldham, J. M., et al. (2024) · medRxiv · doi:10.1101/2024.10.12.24315151 · Cited by 2
Rutherford, E. N., Sun, D., Lim, K., Edgar, J. R., Matesic, L. E., Marciniak, S. J., Rawlins, E. L., & Dickens, J. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.22.665497 · Cited by 2
Sánchez-Vazquez, R., García-Oteyza, S. B., Serrano, R., Flores, J. M., Martínez, P., & Blasco, M. A. (2025) · Genes & Development · doi:10.1101/gad.352855.125 · Cited by 2
Alber, A. B., Kwong, G., Gupta, V. K., Dooley, P. E., Patel, J., Bawa, P., Minakin, K., Jones, D. L., Gopal, D., Souza, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702837 · Cited by 4
Raparia, K., & Raj, R. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0134-ra · Cited by 1
Fahim, A. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13322 · Cited by 1
Vancheri, C., Bengus, M., Bianchino, L., et al. (2021) · Pulmonary Therapy · doi:10.1007/s41030-021-00155-8 · Cited by 1
Idiopathic Interstitial Pneumonias: A Review of the Past and Emerging Therapies
Sagardia, L., Taylor, B. E., & Mehta, I. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053286 · Cited by 1
Miguel, T. P., POLO, V. O., Lizán, L., et al. (2022) · Open Respiratory Archives · doi:10.1016/j.opresp.2022.100158 · Cited by 1
Therapie der Lungenfibrosen: Interdisziplinäre Diagnostik bessert Therapiechancen
Prasse, A. (2022) · Deutsches Ärzteblatt · doi:10.3238/perspneumo.2022.04.29.01 · Cited by 1
Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis)
Sgalla, G., & Richeldi, L. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1437ed · Cited by 1
Calle, C. A., Rosales, M. F., & Eddyn, R. M. (2023) · Revista americana de medicina respiratoria · doi:10.56538/ramr.vfnq2915 · Cited by 1
Khan, M. A., Ghamdi, B. A., Alhamadi, M., Rajendram, R., Alyami, S., Al-Gamedi, M., Al-Harbi, A., & Al-Jahdali, H. H. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_264_22 · Cited by 3
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.